Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab plus fluoropyrimidine/platinum chemotherapy versus chemotherapy in first-line HER2-negative advanced or recurrent gastric cancer
jRCT2031210458Phase 3Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in gastric cancer (GC) and esophagogastric junction cancer (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Overall survival. Started Nov 2021; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2031210458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210458.